Coronavirus (COVID-19) Collection
Seroprevalence of infection-induced SARS-CoV-2 antibodies among health care users of Northern Italy: results from two serosurveys (October-November 2019 and September-October 2021)COVID-19, caused by SARS-CoV-2, was declared a public health emergency of international concern on January 30, 2020. As of June 12, 2022, there have been 533,160,628 confirmed cases worldwide, including over 6 million deaths (WHO, 2022).
SARS-CoV-2 seroprevalence and associated risk factors in periurban Zambia: a population-based studyWe nested a seroprevalence survey within the TREATS (Tuberculosis Reduction through Expanded Antiretroviral Treatment and Screening) project. We aimed to measure the seroprevalence of SARS-CoV-2 infection and investigate associated risk factors in one community (population ∼27,000) with high prevalence of TB/HIV in Zambia.
Seroprevalence of IgG antibodies against SARS-CoV-2 in India, March 2020 to August 2021: a systematic review and meta-analysisCOVID-19 caused by SARS-CoV-2 virus has spread rapidly across the world since December 2019. The pandemic has overwhelmed the health systems of developed and developing nations alike (Chowdhury & Jomo, 2020). Countries lacked the required ability to test, trace, treat, and isolate/quarantine the infected population. It is well established that true community burden would remain higher than the reported caseload owing to various reasons like asymptomatic infections, the differences in testing strategies by time and place, variable sensitivities of laboratory tests used for diagnosis, and other factors influencing the health-seeking behaviour of the population (M.
Community seroprevalence and risk factors for SARS-CoV-2 infection in different subpopulations in Vellore, India, and their implications for future preventionThe coronavirus disease 2019 (COVID-19) pandemic has caused an unprecedented public health challenge in India, with over 32 million confirmed cases and over 400 000 deaths as of the end of August 2021 (JHU CSSE, 2021). India imposed a universal, strict lockdown, which began in March 2020 as the pandemic started, and lasted for several months.This provided a window of opportunity to prepare the healthcare system and helped in flattening the epidemic curve and reducing mortality. After the first wave — by the end of January 2021 — a low case fatality rate (CFR) of 1.4% was reported, with 154, 428 deaths among the 10.76 million cases (Purkayastha et al., 2021).
SARS-CoV-2 seroprevalence among 7950 healthcare workers in the Region of Southern DenmarkCoronavirus disease 2019 (COVID-19) surged as an ongoing worldwide pandemic throughout 2020 (Park et al., 2020; Siordia, 2020). The first Danish cases were reported in late February 2020, and the initial spread of infection most likely originated from ski tourists returning from Northern Italy and Austria (Madsen et al., 2021). The first epidemic wave in Denmark peaked in late March and early April, with 9.2 patients admitted to hospital per 100 000 population (Madsen et al., 2021; Statens Serum Institut 2021).
High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, KenyaSixteen months after the emergence of the coronavirus disease of 2019 (COVID-19), severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection had been confirmed in almost 140 million people globally and led to >2.9 million deaths (WHO, 2021a). In April 2020, the World Bank expressed concern that high virus transmission posed the greatest risk in densely populated urban areas, especially those with poor infrastructure and service delivery systems (The World Bank, 2020). In Africa, the urban population stood at 588 million people in 2020, with 50% of this population living in informal settlements, while 70% of the population were self-employed or working in unregulated sectors, making them vulnerable to income losses and less able to adhere to COVID-19 restrictions and lockdowns (United Nations et al., 2019).
SARS-CoV-2 seroprevalence and associated factors in Manaus, Brazil: baseline results from the DETECTCoV-19 cohort studyInfectious diseases have a profound impact on humans, particularly vulnerable populations (Fauci and Morens, 2012). The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and a lack of effective treatment and non-pharmaceutical interventions to curb transmission have led to an exponential increase in the burden of coronavirus disease 2019 (COVID-19) worldwide (Hsiang et al., 2020; Kraemer et al., 2020; Bo et al., 2021).
High seroprevalence for SARS-CoV-2 infection in South America, but still not enough for herd immunity!There has been intense discussion about the importance of reaching herd immunity to achieve global population protection status against SARS-CoV-2/COVID-19. For that reason, vaccination coverage and seroprevalence studies are increasing around the world; some of them have shown an increase in the seroprevalence of different populations. For example, a recent study in Jordan (Sughayer et al., 2021) stated the importance of seroprevalence studies for SARS-CoV-2 infection among healthy blood donors.
SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020–January 2021Population-based serosurveys are recommended to estimate the proportion of a population already infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Repeated cross-sectional serosurveys conducted in the same geographical location provide estimates to monitor trends over a period of time (World Health Organization, 2020a). Information from repeated cross-sectional surveys is valuable for public health decision makers to design and revise containment strategies. A meta-analysis undertaken by Chen et al.
Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemicThe coronavirus disease 2019 (COVID-19) pandemic had resulted in more than 147 million cases of confirmed infection, and more than 3 million deaths worldwide as of week 2021-16, 2021 (European Centre for Disease Prevention and Control, 2021).
Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, PakistanThe coronavirus disease 2019 (COVID-19) pandemic has resulted in more than 62 million confirmed cases and over 1.4 million deaths globally, a case fatality rate (CFR) of approximately 5.4% and an infection fatality rate (IFR) of 0.9% (Johns Hopkins University, 2020; Rekatsina et al., 2020). As the world rushed to respond to the global health crisis, the pandemic revealed numerous cracks in healthcare systems (Armocida et al., 2020). Pakistan was one of the first low- and middle-income countries (LMICs) to be affected by the pandemic, and had reported 398,024 cases and 8025 deaths (CFR 2.51%) at the time of writing (Government of Pakistan, 2020; Johns Hopkins University, 2020).
Seroprevalence of SARS-CoV-2 antibody among healthcare workers in a university hospital in Mallorca, Spain, during the first wave of the COVID-19 pandemicCOVID-19 (coronavirus disease, 2019) is a novel viral disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first identified in December 2019 in Wuhan, China (Zhu et al., 2020). Due to its alarming spread, disease severity, number of affected countries, and number of deaths, the World Health Organization (WHO) declared COVID-19 a pandemic on 11th March 2020 (World Health Organization, 2020). To date (15th February 2021), there have been more than 106 million confirmed cases and more than two million deaths worldwide (European Centre for Disease Prevention and control, 2020).
Seroprevalence of antibodies to SARS-CoV-2 among blood donors in the early months of the pandemic in Saudi ArabiaSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a novel coronavirus causing Coronavirus Disease-19 (COVID-19) infection at a pandemic scale. It was first detected in Wuhan city, China, in December 2019 and has since rapidly spread worldwide including the Kingdom of Saudi Arabia (AlJishi and Al-Tawfiq, 2021; AlJishi et al., 2021; Al-Tawfiq and Memish, 2020b). Patients with COVID-19 have a wide clinical spectrum from an asymptomatic or mild infection in most cases to a severe acute respiratory syndrome (SARS) in others (Al-Tawfiq, 2020).